Print
Email
Print Edition Stories
ImmunoGen Inc. is pulling in a $3 million milestone payment from French pharmaceutical giant Sanofi as the Cambridge biotech’s drug target for non-Hodgkin’s lymphoma moves into Phase 2 clinical trials.
The Targeted Antibody Payload (TAP) compound called SAR3419 developed by ImmunoGen is licensed to Sanofi through a larger collaborative deal between the two companies. The drug candidate is made to treat CD19+ non-Hodgkin’s lymphoma and other B-cell malignancies.
The Phase 2 trial is expected to test SAR3419 in treating diffuse large B-cell lymphoma and for B-cell acute lymphoblastic lymphoma.
In Phase 1 trials, SAR3419 returned generally positive results, including a lack of a reduction in blood cell production and overall drug toleration, in patients with non-Hodgkin’s lymphoma, as well as those with rituximab-refractory and ‑responsive disease.
ImmunoGen (Nasdaq: IMGN) announced in September that it had filed with the U.S. Food and Drug Administration for clearance to begin human trials on a potential therapy, called IMGN529, for non-Hodgkins lymphoma and chronic lymphocytic leukemia.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
